Building off of last year’s successful new format, AACE is pleased to announce the newest edition of the AACE Self-Assessment Program (ASAP)!


Submit your paper for presentation at the first annual Endocrine Practice Journal Symposium at the 2023 AACE Annual Meeting in Seattle, WA.


Learn how you can elevate your endocrinology career by participating in AACE consensus statements, guidelines, educational programs, abstracts, and more.


We're seeking authors and a methodology fellow to update the 2017 AACE Clinical Practice Guideline for the Management of Dyslipidemia and Prevention of Cardiovascular Disease. Learn how to apply today!


After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.


Initial research suggests that people with cardiometabolic disease are at increased risk of experiencing complications from infection with COVID-19 and may be more susceptible to contracting the virus.


August 18, 2020 (Latest Update)

COVID-19 Resources: Telehealth, Updates and More

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.


Prasad, M. et al. Triglyceride and Triglyceride/HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease. J Am Heart Assoc. 2019;8:e009442. DOI: 10.1161/JAHA.118.009442.)


Chait, A. and Eckel, R. The Chylomicronemia Syndrome Is Most Often Multifactorial. Ann Intern Med. 2019;170:626-634. doi:10.7326/M19-0203


Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 2019:Cir0000000000000678


Hawley CE, et al. Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines. Drugs Aging 2019


Kim DW, et al. Association between statin treatment and new-onset diabetes mellitus: a population based case-control study. Diabetology & metabolic syndrome 2019; 11:30


Schleyer T, Hui S, Wang J, et al. Quantifying unmet need in statin-treated hyperlipidemia patients and the potential benefit of further LDL-C reduction through an EHR-based retrospective cohort study. J Manag Care Spec Pharm. 2019;25(5):544-554. 


Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812792


Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk.


Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.

https://www.nejm.org/doi/full/10.1056/NEJMoa1803917